CO2017003263A2 - Composición farmacéutica basadas en anamorelina que tienen actividad sobre caquexia causada por cáncer - Google Patents
Composición farmacéutica basadas en anamorelina que tienen actividad sobre caquexia causada por cáncerInfo
- Publication number
- CO2017003263A2 CO2017003263A2 CONC2017/0003263A CO2017003263A CO2017003263A2 CO 2017003263 A2 CO2017003263 A2 CO 2017003263A2 CO 2017003263 A CO2017003263 A CO 2017003263A CO 2017003263 A2 CO2017003263 A2 CO 2017003263A2
- Authority
- CO
- Colombia
- Prior art keywords
- anamorelin
- cancer
- activity
- pharmaceutical composition
- composition based
- Prior art date
Links
- VQPFSIRUEPQQPP-MXBOTTGLSA-N anamorelin Chemical compound C([C@@]1(C(=O)N(C)N(C)C)CN(CCC1)C(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(C)(C)N)C1=CC=CC=C1 VQPFSIRUEPQQPP-MXBOTTGLSA-N 0.000 title abstract 4
- 229950005896 anamorelin Drugs 0.000 title abstract 4
- 108010052640 anamorelin Proteins 0.000 title abstract 4
- 206010006895 Cachexia Diseases 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 208000029499 cancer-related condition Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462045976P | 2014-09-04 | 2014-09-04 | |
| PCT/US2015/047435 WO2016036598A1 (en) | 2014-09-04 | 2015-08-28 | Medical treatments based on anamorelin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017003263A2 true CO2017003263A2 (es) | 2017-07-28 |
Family
ID=55436476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0003263A CO2017003263A2 (es) | 2014-09-04 | 2017-04-03 | Composición farmacéutica basadas en anamorelina que tienen actividad sobre caquexia causada por cáncer |
Country Status (44)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9492535B2 (en) | 2013-03-14 | 2016-11-15 | Aimmune Therapeutics, Inc. | Peanut formulations and uses thereof |
| HUE046894T2 (hu) | 2014-09-04 | 2020-04-28 | Helsinn Healthcare Sa | Anamorelinen alapuló gyógyászati kezelések |
| WO2020037151A1 (en) | 2018-08-16 | 2020-02-20 | Aimmune Therapeutics, Inc. | Peanut oral immunotherapy with maintenance dose |
| US12226448B2 (en) | 2018-12-20 | 2025-02-18 | Société des Produits Nestlé S.A. | Peanut oral immunotherapy dosing schedule for missed doses |
| US11229673B2 (en) | 2019-05-10 | 2022-01-25 | Société des Produits Nestlé S.A. | Methods for improving the quality of life of a patient with a peanut allergy |
| CN115569119A (zh) | 2019-08-30 | 2023-01-06 | 赫尔森保健股份公司 | 具有改善稳定性的阿拉莫林片剂的生产方法 |
| CA3158632A1 (en) | 2019-10-24 | 2021-04-29 | Toray Industries, Inc. | Therapeutic or prophylactic agent for cachexia |
| JP2024534464A (ja) * | 2021-09-17 | 2024-09-20 | 小野薬品工業株式会社 | 食欲不振／悪液質患者における患者報告アウトカムに関する臨床的に意味のある改善を判定し、提供する方法 |
| WO2025004650A1 (ja) * | 2023-06-28 | 2025-01-02 | 日清オイリオグループ株式会社 | 中高年者の疲労感を軽減するための剤及び組成物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303620B1 (en) | 1998-05-11 | 2001-10-16 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| ECSP993020A (es) | 1999-06-16 | 1999-08-12 | Terapia de combinacion para la fragilidad musculoesqueletica | |
| ECSP993021A (es) | 1999-06-16 | 1999-08-12 | Combinaciones terapeuticas para la fragilidad musculoesqueletica | |
| US20010020012A1 (en) | 2000-02-01 | 2001-09-06 | Andersen Maibritt Bansholm | Use of compounds for the regulation of food intake |
| EP1660117A2 (en) * | 2003-08-06 | 2006-05-31 | Gastrotech Pharma A/S | Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite |
| CN1863550A (zh) * | 2003-08-06 | 2006-11-15 | 加斯特罗泰克药物公司 | 促分泌素样生长素释放肽在癌症恶病质中以及在刺激食欲方面的应用 |
| KR20070010151A (ko) | 2004-03-30 | 2007-01-22 | 사파이어 세라퓨틱스, 인크. | 성장 호르몬 분비촉진제를 이용하여 ｃ-반응성 단백질을감소시키는 방법 |
| EP1768976B1 (en) * | 2004-06-29 | 2017-04-26 | Helsinn Healthcare S.A. | Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide |
| MX2009008561A (es) * | 2007-02-13 | 2010-01-15 | Helsinn Therapeutics Us Inc | Metodo para tratar trastornos proliferativos celulares utilizando secretagogos. |
| TWI429436B (zh) * | 2007-04-10 | 2014-03-11 | Helsinn Therapeutics Us Inc | 使用生長激素促泌素治療或預防嘔吐之方法 |
| JO3353B1 (ar) * | 2012-04-20 | 2019-03-13 | Ono Pharmaceutical Co | شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي |
| CN104470524A (zh) * | 2012-05-25 | 2015-03-25 | 拉夸里亚创药株式会社 | 用于治疗胃酸缺乏症的生长激素释放肽受体激动剂 |
| HUE046894T2 (hu) | 2014-09-04 | 2020-04-28 | Helsinn Healthcare Sa | Anamorelinen alapuló gyógyászati kezelések |
-
2015
- 2015-08-28 HU HUE15838548A patent/HUE046894T2/hu unknown
- 2015-08-28 MD MDA20170025A patent/MD4710C1/ro active IP Right Grant
- 2015-08-28 BR BR112017003552A patent/BR112017003552A2/pt not_active Application Discontinuation
- 2015-08-28 PL PL15838548T patent/PL3188599T3/pl unknown
- 2015-08-28 MX MX2017002825A patent/MX361741B/es active IP Right Grant
- 2015-08-28 LT LT15838548T patent/LT3188599T/lt unknown
- 2015-08-28 HR HRP20192345TT patent/HRP20192345T1/hr unknown
- 2015-08-28 CR CR20170121A patent/CR20170121A/es unknown
- 2015-08-28 ES ES15838548T patent/ES2761777T3/es active Active
- 2015-08-28 PE PE2017000359A patent/PE20171109A1/es unknown
- 2015-08-28 MA MA40607A patent/MA40607B1/fr unknown
- 2015-08-28 CN CN202111026050.3A patent/CN113577073A/zh active Pending
- 2015-08-28 EP EP15838548.4A patent/EP3188599B1/en active Active
- 2015-08-28 ME MEP-2019-372A patent/ME03597B/me unknown
- 2015-08-28 DK DK15838548T patent/DK3188599T3/da active
- 2015-08-28 GE GEAP201514459A patent/GEP20186939B/en unknown
- 2015-08-28 UA UAA201702308A patent/UA120765C2/uk unknown
- 2015-08-28 EP EP19183144.5A patent/EP3590338A3/en not_active Withdrawn
- 2015-08-28 KR KR1020187020062A patent/KR102234319B1/ko active Active
- 2015-08-28 SG SG11201701567UA patent/SG11201701567UA/en unknown
- 2015-08-28 CA CA2959158A patent/CA2959158A1/en active Pending
- 2015-08-28 SI SI201530994T patent/SI3188599T1/sl unknown
- 2015-08-28 AU AU2015312231A patent/AU2015312231B2/en active Active
- 2015-08-28 PT PT158385484T patent/PT3188599T/pt unknown
- 2015-08-28 CN CN201580059744.3A patent/CN107205389A/zh active Pending
- 2015-08-28 EA EA201790352A patent/EA035578B1/ru unknown
- 2015-08-28 CN CN202111027023.8A patent/CN113577074A/zh active Pending
- 2015-08-28 US US14/839,038 patent/US9675600B2/en active Active
- 2015-08-28 TN TN2017000040A patent/TN2017000040A1/en unknown
- 2015-08-28 KR KR1020177008748A patent/KR101881264B1/ko active Active
- 2015-08-28 KR KR1020217008765A patent/KR102307275B1/ko active Active
- 2015-08-28 CN CN201710646685.0A patent/CN107375285A/zh active Pending
- 2015-08-28 MY MYPI2017700714A patent/MY187167A/en unknown
- 2015-08-28 RS RS20191688A patent/RS59751B1/sr unknown
- 2015-08-28 WO PCT/US2015/047435 patent/WO2016036598A1/en not_active Ceased
- 2015-08-28 CN CN201811119404.7A patent/CN109172575A/zh active Pending
- 2015-08-28 JP JP2017512679A patent/JP6356907B2/ja active Active
- 2015-08-28 AP AP2017009772A patent/AP2017009772A0/en unknown
- 2015-08-30 JO JOP/2015/0210A patent/JO3541B1/ar active
- 2015-09-01 TW TW104128838A patent/TWI639429B/zh active
- 2015-09-02 UY UY0001036286A patent/UY36286A/es not_active Application Discontinuation
- 2015-09-03 AR ARP150102818A patent/AR103118A1/es unknown
-
2017
- 2017-02-20 IL IL250692A patent/IL250692B/en active IP Right Grant
- 2017-03-02 CL CL2017000494A patent/CL2017000494A1/es unknown
- 2017-03-02 PH PH12017500392A patent/PH12017500392B1/en unknown
- 2017-03-03 DO DO2017000055A patent/DOP2017000055A/es unknown
- 2017-03-03 NI NI201700024A patent/NI201700024A/es unknown
- 2017-03-03 SV SV2017005400A patent/SV2017005400A/es unknown
- 2017-03-30 EC ECIEPI201719893A patent/ECSP17019893A/es unknown
- 2017-04-03 CO CONC2017/0003263A patent/CO2017003263A2/es unknown
- 2017-05-09 US US15/590,025 patent/US10278964B2/en active Active
-
2018
- 2018-06-14 JP JP2018113592A patent/JP6923486B2/ja active Active
-
2019
- 2019-02-14 US US16/275,669 patent/US10894041B2/en active Active
- 2019-12-16 CY CY20191101321T patent/CY1122746T1/el unknown
-
2020
- 2020-12-11 US US17/119,482 patent/US11723902B2/en active Active
-
2021
- 2021-02-26 JP JP2021029775A patent/JP7044918B2/ja active Active
-
2023
- 2023-06-22 US US18/212,720 patent/US20240024303A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017003263A2 (es) | Composición farmacéutica basadas en anamorelina que tienen actividad sobre caquexia causada por cáncer | |
| MX2024010140A (es) | Nuevos metodos. | |
| MX2021002322A (es) | Nuevos metodos. | |
| MX377576B (es) | Formulaciones de pridopidina de liberación modificada. | |
| MX370953B (es) | Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes. | |
| MX2015009045A (es) | Composiciones y metodos para tratar el dolor severo. | |
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| MX2015011905A (es) | Uso de levocetirizina y montelukast en el tratamiento de la vasculitis. | |
| CA3010568A1 (en) | Oromucosal nanofiber carriers for therapeutic treatment | |
| MX382776B (es) | Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica. | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| ZA201906153B (en) | Pharmaceutical compositions for combination therapy | |
| MX2017008516A (es) | Anestesico a base de tetracaina. | |
| GT201700041A (es) | Tratamientos médicos a base de anamorelina | |
| EA201991866A1 (ru) | Комбинированная терапия | |
| EA201990553A1 (ru) | Применение придопидина для лечения ухудшения функциональной способности | |
| BR112015002384A8 (pt) | combinações farmacêuticas compreendendo um inibidor de b-raf, um inibidor de egfr e, opcionalmente, um inibidor de pi3k-alfa, e seus usos". | |
| EA201692163A1 (ru) | Лекарственное средство для лечения пациентов с тиннитусом | |
| MX377674B (es) | Formulacion de tableta oral solida de rosuvastatina de liberacion inmediata y metformina de liberacion prolongada. |